{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["161(7)"],"submitter":["Gooderham MJ"],"pubmed_abstract":["<h4>Importance</h4>Current topical treatments for scalp psoriasis are limited by formulation, efficacy, and/or safety.<h4>Objective</h4>To assess safety and efficacy of roflumilast foam, 0.3%, in patients with psoriasis of the scalp and body.<h4>Design, setting, and participants</h4>This was a phase 3 double-blinded, vehicle-controlled randomized clinical trial conducted between August 24, 2021, and June 3, 2022, at 49 sites in Canada and the US. Eligible participants were 12 years and older with plaque psoriasis affecting up to 25% of the scalp and body, at least 10% of the scalp, and up to 20% of nonscalp areas, with a minimum Scalp-Investigator Global Assessment (S-IGA) score of 3 (moderate), and minimum Body-IGA (B-IGA) score of 2 (mild). Data analyses were performed from September 9 t"],"journal":["JAMA dermatology"],"pagination":["698-706"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12060019"],"repository":["biostudies-literature"],"pubmed_title":["Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial."],"pmcid":["PMC12060019"],"pubmed_authors":["Krupa D","DuBois J","Bagel J","Alonso-Llamazares J","Burnett P","Bukhalo M","Gooderham MJ","Kato S","Ferris LK","Green L","Seal MS","Soung J","Bhatia N","Papp KA","Lockshin B","Chu DH","Loo WJ","Snyder S","Kircik LH","Berk DR"],"additional_accession":[]},"is_claimable":false,"name":"Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.","description":"<h4>Importance</h4>Current topical treatments for scalp psoriasis are limited by formulation, efficacy, and/or safety.<h4>Objective</h4>To assess safety and efficacy of roflumilast foam, 0.3%, in patients with psoriasis of the scalp and body.<h4>Design, setting, and participants</h4>This was a phase 3 double-blinded, vehicle-controlled randomized clinical trial conducted between August 24, 2021, and June 3, 2022, at 49 sites in Canada and the US. Eligible participants were 12 years and older with plaque psoriasis affecting up to 25% of the scalp and body, at least 10% of the scalp, and up to 20% of nonscalp areas, with a minimum Scalp-Investigator Global Assessment (S-IGA) score of 3 (moderate), and minimum Body-IGA (B-IGA) score of 2 (mild). Data analyses were performed from September 9 t","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-06-03T02:45:20.959Z","creation":"2025-09-01T03:05:40.652Z"},"accession":"S-EPMC12060019","cross_references":{"pubmed":["40332898"],"doi":["10.1001/jamadermatol.2025.1136"]}}